GlassScriptPhysician profile
Dawinder S Sohal
NPI 1962411215
$684.06
in general payments reported to CMS, 2019-2025
13 companies · $38.51 in 2025
The $38.51 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $31.99 · 2021: $12.97 · 2022: $75.24 · 2023: $80.54 · 2024: $260 · 2025: $38.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353 · Education: $26.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.62 |
| Education | $26.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $217.85 | 2019-2024 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $105.37 | 2023-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $101.17 | 2019-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $55.30 | 2024 | |
| Ardelyx, INC. | $43.39 | 2023 | Ibsrela |
| Horizon Therapeutics Plc | $31.38 | 2020-2021 | |
| Amgen INC. | $28.13 | 2019 | |
| Baxter Healthcare | $22.52 | 2024 | Renal - Extraneal Solution |
| Calliditas Therapeutics US INC. | $21.96 | 2024 | |
| Vifor Pharma, INC. | $20.72 | 2023 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $17.98 | 2024 | Jynarque |
| Nxstage Medical, INC. | $16.63 | 2025 | Liberty Select Cycler, Nxstage System One |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawinder Sohal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.